Answers are grounded in this paper and cite their sources.
Background Hypophosphatasia (HPP) is a rare genetic disorder caused by mutation in the ALPL (Alkaline Phosphatase, Biomineralization Associated) gene, resulting in low activity of tissue nonspecific alkaline phosphatase (TNSALP). Delayed diagnosis and misdiagnosis are common due to its diverse and nonspecific clinical presentations We report an adult patient with longstanding symptoms and delayed recognition of HPP who demonstrated clinical improvement with enzyme replacement therapy. Case Presentation A 44-year-old woman with hypothyroidism on levothyroxine presented with chronic fatigue, low energy, and diffuse musculoskeletal pain. Laboratory testing showed persistently low alkaline phosphatase (<40 U/L) and elevated vitamin B6 (44 ng/mL). Further history revealed a childhood leg fracture, abnormal chest/rib cage morphology, premature tooth loss, and recurrent dental caries. Although no pathogenic ALPL mutation was identified, her clinical features and biochemical findings were highly suggestive of hypophosphatasia. She was diagnosed with hypophosphatasia and was started on weight-based Asfotase alfa therapy, with improvement on musculoskeletal pain, fatigue, walking tolerance, daily functioning and dental/jaw pain. Discussion Adult hypophosphatasia may present with chronic musculoskeletal pain, fatigue, and dental abnormalities. Persistently low alkaline phosphatase level is a hallmark of the disease. Asfotase alfa enzyme replacement therapy is available for the treatment. Conclusion This case highlights the importance of maintaining a high index of suspicion in patients presenting with chronic musculoskeletal pain or persistently low serum alkaline phosphatase levels. Early recognition and treatment are essential to improve functional outcomes, reduce complications, and enhance quality of life.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.